Baxter, Cerus Platelet Viral Inactivation System Enters Phase III Trial
This article was originally published in The Gray Sheet
Executive Summary
Baxter's Fenwal Division plans to manufacture, market and distribute a system intended to inactivate viruses, bacteria and other pathogens in platelet concentrations.
You may also be interested in...
Nexell Planning To Seek Labeling Expansion For Isolex 300i In 2001
Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.
Baxter To Distribute Ceprate During Cellpro Bankruptcy Until Isolex Approval
Baxter will distribute Cellpro's Ceprate stem cell concentration system worldwide pending approval of Nexell's Isolex stem cell collection system under a bankruptcy plan for CellPro.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.